[SCHEDULE 13G] Rein Therapeutics, Inc. Passive Investment Disclosure (>5%)
ADAR1 reports 5.3% stake in Rein Therapeutics
ADAR1 Capital Management, LLC and its manager, Daniel Schneeberger, report beneficial ownership in Rein Therapeutics, Inc. They report 4,500,000 shares of common stock, representing 5.3% of the company’s common stock outstanding.
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
ADAR1 Capital Management, LLC and its manager, Daniel Schneeberger, report beneficial ownership in Rein Therapeutics, Inc. They report 4,500,000 shares of common stock, representing 5.3% of the company’s common stock outstanding.
The shares are held by private investment funds managed by ADAR1 Capital Management and may be deemed to be indirectly beneficially owned by both ADAR1 Capital Management and Mr. Schneeberger. The percentage is based on 85,767,032 shares of common stock outstanding as of June 30, 2026.
Key Figures
Shares beneficially owned:4,500,000 sharesPercent of class:5.3%Shares outstanding:85,767,032 shares+3 more
6 metrics
Shares beneficially owned4,500,000 sharesCommon stock of Rein Therapeutics reported by ADAR1 Capital Management and Daniel Schneeberger
Percent of class5.3%Portion of Rein Therapeutics common stock beneficially owned by the reporting persons
Shares outstanding85,767,032 sharesRein Therapeutics common stock outstanding as of June 30, 2026
Shared voting power4,500,000 sharesShares over which the reporting persons share voting power
Shared dispositive power4,500,000 sharesShares over which the reporting persons share dispositive power
Par value per share$0.001 per sharePar value of Rein Therapeutics common stock
Key Terms
beneficially owned, shared voting power, shared dispositive power, control person, +1 more
5 terms
beneficially ownedfinancial
"Such securities may be deemed to be indirectly beneficially owned by ADAR1 Capital Management, LLC."
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
shared voting powerfinancial
"Shared Voting Power 4,500,000.00"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
shared dispositive powerfinancial
"Shared Dispositive Power 4,500,000.00"
control personfinancial
"Mr. Schneeberger is filing this as a control person in respect of shares beneficially owned by ADAR1 Capital Management"
A control person is an individual or entity that can significantly influence a company’s decisions and direction through ownership, voting power, or contractual rights—think of them as the captain who can steer the ship. Investors care because a control person’s choices affect corporate strategy, board appointments, and transactions that can raise or lower a stock’s value, and they often carry additional legal responsibilities and disclosure requirements to protect other shareholders.
investment adviserfinancial
"ADAR1 Capital Management, an investment adviser as described in ss. 240.13d-1(b)(1)(ii)(E)"
An investment adviser is a person or firm that professionally manages money and gives recommendations about buying, selling, or holding investments. Like a financial coach or guide, they have a legal duty to act in a client's best financial interest, so their advice, fees and potential conflicts can directly affect returns and risk — making their role important for investors who want informed, accountable help with portfolios.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What ownership stake in Rein Therapeutics (RNTX) does ADAR1 Capital Management report?
ADAR1 Capital Management reports beneficial ownership of 4,500,000 shares of Rein Therapeutics common stock, representing 5.3% of the outstanding common stock based on 85,767,032 shares outstanding as of June 30, 2026.
Who are the reporting persons in this Rein Therapeutics (RNTX) ownership disclosure?
The reporting persons are ADAR1 Capital Management, LLC, a Texas limited liability company, and Daniel Schneeberger, its sole manager and a citizen of Switzerland. Both may be deemed to beneficially own the same 4,500,000 shares.
How many Rein Therapeutics (RNTX) shares are outstanding for the ownership calculation?
The reported ownership percentage is based on 85,767,032 shares of Rein Therapeutics common stock outstanding as of June 30, 2026, as reported in the company’s Quarterly Report for that period.
How is voting and dispositive power over Rein Therapeutics (RNTX) shares allocated?
The reporting persons have 0 sole voting or dispositive power and 4,500,000 shares of shared voting and shared dispositive power, reflecting shares held by private investment funds managed by ADAR1 Capital Management.
Does Daniel Schneeberger directly own Rein Therapeutics (RNTX) shares?
The 4,500,000 Rein Therapeutics shares are owned directly by private investment funds managed by ADAR1 Capital Management and may be deemed to be indirectly beneficially owned by Daniel Schneeberger as the sole manager of ADAR1.
What class of Rein Therapeutics (RNTX) securities is covered in this ownership report?
The report covers Rein Therapeutics common stock, with a par value of $0.001 per share, identified by CUSIP number 00887A204.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
Rein Therapeutics, Inc.
(Name of Issuer)
Common Stock, $0.001 par value per share
(Title of Class of Securities)
00887A204
(CUSIP Number)
06/30/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
00887A204
1
Names of Reporting Persons
ADAR1 Capital Management, LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
TEXAS
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
4,500,000.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
4,500,000.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
4,500,000.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.3 %
12
Type of Reporting Person (See Instructions)
IA, OO
Comment for Type of Reporting Person: The amounts reported in boxes 6, 8, and 9 represent 4,500,000 shares of common stock, $0.001 par value per share ("Common Stock"), of Rein Therapeutics, Inc. (the "Issuer") owned directly by private investment funds managed by ADAR1 Capital Management, LLC. Such securities may be deemed to be indirectly beneficially owned by ADAR1 Capital Management, LLC.
The percentage in box 11 is based on 85,767,032 shares of Common Stock outstanding as of June 30, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2026, filed with the Securities and Exchange Commission on August 14, 2026.
SCHEDULE 13G
CUSIP Number(s):
00887A204
1
Names of Reporting Persons
Daniel Schneeberger
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
SWITZERLAND
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
4,500,000.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
4,500,000.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
4,500,000.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.3 %
12
Type of Reporting Person (See Instructions)
HC, IN
Comment for Type of Reporting Person: The amounts reported in boxes 6, 8, and 9 represent 4,500,000 shares of common stock, $0.001 par value per share ("Common Stock"), of Rein Therapeutics, Inc. (the "Issuer") owned directly by private investment funds managed by ADAR1 Capital Management, LLC. Such securities may be deemed to be indirectly beneficially owned by Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC.
The percentage in box 11 is based on 85,767,032 shares of Common Stock outstanding as of June 30, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2026, filed with the Securities and Exchange Commission on August 14, 2026.
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Rein Therapeutics, Inc.
(b)
Address of issuer's principal executive offices:
12407 N. Mopac Expy., Suite 250, #390, Austin, TX 78758
Item 2.
(a)
Name of person filing:
This Schedule is being filed on behalf of each of the following persons (each, a "Reporting Person" and collectively, the "Reporting Persons"):
(i) ADAR1 Capital Management, LLC ("ADAR1 Capital Management"); and
(ii) Daniel Schneeberger ("Mr. Schneeberger").
(b)
Address or principal business office or, if none, residence:
The address of the principal business office of each of the Reporting Persons is 3503 Wild Cherry Drive, Building 9, Austin, Texas 78738.
(c)
Citizenship:
(i) ADAR1 Capital Management is a Texas limited liability company; and
(ii) Mr. Schneeberger is a citizen of Switzerland.
(d)
Title of class of securities:
Common Stock, $0.001 par value per share
(e)
CUSIP Number(s):
00887A204
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
The information contained on the cover pages of this Schedule 13G is incorporated herein by reference.
(b)
Percent of class:
The information contained on the cover pages of this Schedule 13G is incorporated herein by reference.
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
The information contained on the cover pages of this Schedule 13G is incorporated herein by reference.
(ii) Shared power to vote or to direct the vote:
The information contained on the cover pages of this Schedule 13G is incorporated herein by reference.
(iii) Sole power to dispose or to direct the disposition of:
The information contained on the cover pages of this Schedule 13G is incorporated herein by reference.
(iv) Shared power to dispose or to direct the disposition of:
The information contained on the cover pages of this Schedule 13G is incorporated herein by reference.
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.
Mr. Schneeberger is filing this Schedule 13G as a control person in respect of shares beneficially owned by ADAR1 Capital Management, an investment adviser as described in ss. 240.13d-1(b)(1)(ii)(E).
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
